Expanded Access Growth WideTrial specializes in large-scale Expanded Access programs, presenting a clear growth path for pre-approval treatment access partnerships with development-stage drug and device companies seeking real-world data and broad patient reach.

Data Value Proposition The programs generate vast secondary clinical data that can support label claims and inform further research, offering a compelling value proposition to pharma and biotech teams prioritizing data-driven regulatory and commercial insights.

SMB to Niche Opportunity With a lean team and revenue in the mid single to low double digits, WideTrial can target small to mid-sized development-stage companies looking for turnkey, faster-to-scale access programs rather than broad enterprise trials.

Competitive Positioning Compared to large CROs, WideTrial's niche focus on Expanded Access and patient-centric access programs can be marketed as a flexible, cost-effective companion for companies aiming to enhance patient access and real-world evidence generation.

Tech and Compliance Readiness The existing tech stack and regulatory-aligned model position WideTrial to offer secure, compliant, and scalable program delivery, enabling sales pitches around speed-to-deployment, data integrity, and patient safety in Expanded Access initiatives.